P. Shanmukhi 1*, M. V. Nagabhushanam 1, K. Ashok 2, M. Beena Devi 1
- D.C.R.M Pharmacy College, Inkollu - 523 167, Prakasam Dt., Andhra Pradesh, India
- QIS College of Pharmacy, Ongole - 523 001, Prakasam Dt., Andhra Pradesh, India
Abstract
In view of increasing bioavailability and percentage drug release by lymphatic drug delivery, Fosinopril loaded solid lipid nanoparticles were prepared by solvent emulsification and evaporation method. In vitro drug release studies revealed that 80% of the drug was being released from the optimized Fosinopril loaded solid lipid nanoparticles (SLNs) in 24hours. Optimized formulation and process parameters resulted in the production of Fosinopril loaded solid lipid nanoparticles with average particle size of 178.8 nm, zeta potential of -21mV and entrapment efficiency of 91.64% of 10 mg loading. In vitro characterization was carried out to evaluate the stability and release characteristics and kinetics. To analyze the release kinetics of drug from SLNs, drug release data was fitted into zero order, Korsmeyer-Peppas equation. Possible mechanisms for drug release might be anomalous diffusion or non-fickian diffusion. FTIR spectra, DSC thermograms revealed no significant interaction between drug and excipients. TEM photographs exhibited nanosized particles of Fosinopril. The stability studies performed for optimized SLN formulation at 4�C, 25�C, showed no significant change in % entrapment efficiency for one month. So, it was concluded that the optimized SLN formulation offers an efficient mode of delivery to the lipophilic antihypertensive drug, Fosinopril.
